Jan 12, 2022 / 10:15PM GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon and good evening. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today, at JPMorgan conference, I've got the pleasure of introducing the MorphoSys presentation and Q&A.
So we can have MorphoSys' CEO, Jean-Paul Kress, joining us at this 20-minute presentation, 20 minutes of Q&A afterwards and will be joined by the Board of management team.
And with that, I said, thanks a lot for joining us today, Jean-Paul, and looking forward to the presentation.
Jean-Paul Kress - MorphoSys AG - Chairman of Management Board, MD & CEO
Thank you, James. It's a pleasure to be here today to share our exciting progress and plans for the future.
On Slide 2, you can find our forward-looking statements before we begin on Slide 3.
At MorphoSys, we are working every day to bring new medicines and hope to people living with cancer. Our goal is to have a profound impact on the lives of cancer patients. We
MorphoSys AG at JPMorgan Healthcare Conference Transcript
Jan 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers